M&T Bank’s Rhythm Pharmaceuticals RYTM Stock Holding History

M&T Bank’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,101	Closed	-$225K	–	1787
2025 Q4	$225K	Buy	+2,101	New	+$223K	﹤0.01%	1516

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

M&T Bank's RYTM Position: Q1 2026 in Review

M&T Bank sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 2,101 shares — an estimated $225K sold.

M&T Bank first reported a position in RYTM in Q4 2025 and held it in 1 quarter. The position peaked at $225K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

M&T Bank reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
M&T Bank sold 2,101 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $225K.
M&T Bank first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 1 quarter.
M&T Bank's Rhythm Pharmaceuticals position peaked at $225K in Q4 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on M&T Bank's 13F filing for Q1 2026, filed 12 May 2026.